The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%

Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.

Start Date10 Nov 2025

Sponsor / Collaborator-

JPRN-jRCTs031240193 / RecruitingNot ApplicableIIT

ROCK inhibitor (ripasudil)-Alpha2 adrenoceptor agonist (brimonidine) fixed-dose combination ophthalmic solution v.s. Beta-blocker (timolol)-Carbonic anhydrase inhibitor (dorzolamide) fixed-dose combination ophthalmic solution comparison study on intraocular pressure lowering efficacy - ROCK-ABC study

Start Date28 Jun 2024

Sponsor / Collaborator-

NCT06730516 / CompletedEarly Phase 1IIT

Optic Nerve Head Perfusion Following Treatment with Latanoprost 0.005% Versus Brimionidin Tartrate 0.2% in Primary Open Angle Glaucoma: an Optical Coherence Tomography Angiography Study

This study aimed to evaluate the effects of topical Latanoprost 0.005 % versus Brimionidin tartrate 0.2% on perfusion of optic nerve head This prospective interventional randomized study included 56 naive patients recently diagnosed with bilateral primary open angle glaucoma equally divided into two groups with 28 patients in each group

Start Date24 Jun 2024

Sponsor / Collaborator

Zagazig University

100 Clinical Results associated with Brimonidine Tartrate

100 Translational Medicine associated with Brimonidine Tartrate

100 Patents (Medical) associated with Brimonidine Tartrate

2,127

Literatures (Medical) associated with Brimonidine Tartrate

01 Jan 2025·COLLOIDS AND SURFACES B-BIOINTERFACES

Anti-oxidative mesoporous polydopamine-based hypotensive nano-eyedrop for improved glaucoma management

Article

Author: Chen, Yangjun ; Nan, Kaihui ; Ding, Xiaoxu ; Huang, Yate ; Ma, Feiyan ; Wang, Xiaoxue ; Zhang, Xuehan ; Zhu, Li

Conventional hypotensive eye drops remain suboptimal for glaucoma management, primarily due to their limited intraocular bioavailability and the growing concern regarding ocular surface side effects. Therefore, there is an urgent need to develop innovative intraocular pressure (IOP)-lowering formulations that not only possess enhanced corneal penetration ability but also provide ocular surface protection. Herein, anti-oxidative mesoporous polydopamine nanoparticles (MPDA NPs) were explored as a nano-carrier for Brimonidine to address the above issues. Nearly monodisperse MPDA NPs with obvious nanopores were successfully prepared by template-removal method and used for encapsulation of Brimonidine benefiting from their high specific surface area. Interestingly, the PEGylated and drug loaded MPDA-PEG@Brim NPs showed a near neutral surface charge, which is expected to enhance intraocular drug delivery. Consequently, much higher concentration of Brimonidine in the aqueous humor was found after topical administration of MPDA-PEG@Brim nano-dispersion as compared to free Brimonidine solution. Accordingly, superior IOP reduction effect was achieved for the nano-formulation in both hypertensive and normotensive rat eyes. Moreover, MPDA-PEG NPs showed good capability in scavenging diverse free radicals, alleviating intracellular oxidative stress, and mitigating ocular surface oxidative level in a mouse model of preservative-induced dry eye. In addition, the excellent biosafety of this novel Brimonidine nanodrug was confirmed both in vitro and in vivo. Therefore, the present work may shed light on the development of next generation hypotensive formulations for extended ocular surface protection and glaucoma management.

01 Jan 2025·JOURNAL OF PHARMACEUTICAL SCIENCES

Measuring erosion of biodegradable polymers in brimonidine drug delivery implants by quantitative proton NMR spectroscopy (q-HNMR)

Article

Author: Samuels, Eric R ; Wang, Hongpeng ; Burgher, Kyle ; Wang, Tao ; Roof, Mike ; Jian, Huahua ; He, Yan ; Pham, Chiem ; Samuels, Eric R.

Erosion of biodegradable polymeric excipients, such as polylactic acid (PLA) and polylactic-co-glycolic acid (PLGA), is generally characterized by microbalance for the remaining mass of PLA and/or PLGA and Gel Permeation Chromatography (GPC) for molecular weight (MW) decrease. For polymer erosion studies of intravitreal sustained release brimonidine implants, however, both microbalance and GPC present several challenges. Mass loss measurement by microbalance does not have specificity for excipient polymers and drug substances. Accuracy of the remaining mass by weighing could also be low due to sample mass loss through retrieval-drying steps, especially at later drug release (DR) time points. When measuring the decrease of polymer MW by GPC, trace amounts of polymeric degradants (oligomers and/or monomers) trapped inside the implants during DR tests may not be measurable due to sensitivity limitations of the GPC detector and column MW range. Previous efforts to measure remained PLGA weight of dexamethasone micro-implants using qNMR with external calibration have been performed, however, these measurements do not account for chemical structure changes (i.e. LA to GA ratio changes from time zero) of PLGA implants during drug release tests. Here, a qNMR method with an internal standard was developed to monitor the following changes in micro-implants during drug release tests: 1. The remaining overall PLA/PLGA mass. 2. The remaining lactic acid (LA), glycolic acid (GA) unit and PLGA's lauryl ester end group percentages. 3. The trace content of PLA/PLGA oligomers as degradants retained in the implants. Unlike microbalance analysis, qNMR has both specificity for drug substance, excipient polymer, and accuracy due to minimal implant loss during sample preparation. Compared to the overall PLA/PLGA remaining mass generally monitored in erosion studies, the percentage of remaining LA, GA, and the ester end group provide more information about the microstructure change (such as hydrophobicity) of PLA/PLGA. Additionally, the qNMR method can complement GPC methods by measuring the change of remaining PLA and PLGA oligomer concentrations in brimonidine implants, with tenfold less sample and no MW cutoff. The qNMR method can be used as a sensitive tool for both polymer excipient characterization and kinetics studies of brimonidine implant erosion.

01 Dec 2024·JOURNAL OF COLLOID AND INTERFACE SCIENCE

Tunable multicolor supramolecular assemblies based on phosphorescence cascade energy transfer for photocatalytic organic conversion and anti-counterfeiting

Article

Author: Yu, Shengsheng ; Niu, Kai-Kai ; Zhu, Rong-Xin ; Liu, Hui ; Ge, Hui-Cong ; Xing, Ling-Bao ; Dong, Ruizhi

Making full use of the captured energy by phosphorescence light-harvesting systems (PLHSs) and the tunable photoluminescence in energy transfer process to realize the multiple applications is still the challenge of PLHSs research. In this study, we have successfully constructed a highly effective PLHS with tunable multicolor luminescence and efficient conversion of photosensitizer types, which can further be used in photocatalytic organic conversion, information anti-counterfeiting and storage. The supramolecular polymer of BDBP-CB[8], which is generated by cucurbit[8]uril (CB[8]) and 4-(4-bromophenyl)-pyridine derivative (BDBP), realizes a phosphorescence emission and a change in luminescence color. Notably, white light emission was achieved and the logic gate systems were constructed utilizing the application of adjustable luminescence color. More interestingly, PLHS can be constructed by employing BDBP-CB[8] as energy donors, Sulforhodamine 101 (SR101) and Cyanine5 (Cy5) as energy acceptors, which results in a remarkably tunable multicolor photoluminescence to achieve the information storage. Furthermore, we have also found that BDBP-CB[8] can serve as type II photosensitizer for the effective production of singlet oxygen (¹O₂) during the photooxidation process of styrene in aqueous environments, attaining a remarkable output rate reaching as high as 89 %. Particularly, compared with ¹O₂ produced by type II photosensitizer BDBP-CB[8], the construction of PLHS can effectively convert type II photosensitizer to type I photosensitizer and efficiently generate superoxide anion radical (O₂^•-), which can be used for photocatalytic cross-dehydrogenative coupling (CDC) reaction in the aqueous solution with a yield of 90 %. Thus, we have created a PLHS that not only achieves tunable multicolor emission for information anti-counterfeiting and storage, but also realizes the conversion of reactive oxygen species (ROS) for different types photocatalytic oxidation reactions.

News (Medical) associated with Brimonidine Tartrate

12 Dec 2024

·www.businesswire.com

Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines

LONDON & SEATTLE--( BUSINESS WIRE )--Tenpoint Therapeutics, Limited (“Tenpoint”) and Visus Therapeutics, Inc., (“Visus”) announce today the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. The merger brings together a late-stage, potentially best-in-class, presbyopia-correcting eye drop, BRIMOCHOL™ PF, on track for NDA filing in 1H, 2025, with a promising pipeline of innovative therapeutics. The merger unites a strong syndicate of institutional investors who are committed to advancing BRIMOCHOL™ PF through marketing approval to patients worldwide while further advancing Tenpoint’s pipeline into clinical development. Tenpoint’s pipeline is comprised of three innovative programs aimed at rejuvenating the aging eye: BRIMOCHOL™ PF, a once-a-day, all day, presbyopia-correcting eye drop with a differentiated profile. BRIMOCHOL™ PF is a unique and patent-protected combination of carbachol, a potent miotic, and brimonidine, an alpha2-agonist. This combination enhances peak efficacy and extends duration; and through the vasoconstrictive properties of brimonidine, helps reduce ocular redness offering a potentially superior treatment for presbyopia. TPT-161, a novel small molecule designed to reverse cataract formation in aging adults. TPT-005, a cell therapy targeting RPE cell replacement for geographic atrophy. To support the continued development of these programs, Tenpoint will shortly embark on a Crossover financing round with insider participation to further fund the completion of clinical studies for BRIMOCHOL™ PF, and the commercialization preparations for a 1H, 2026 launch of BRIMOCHOL™ PF into the US market. As part of the leadership transition, Mr. Henric Bjarke has been appointed Chief Executive Officer of the newly merged company. “As we relaunch Tenpoint as a combined entity with Visus, we are excited to lead with a robust Ophthalmology pipeline, starting with BRIMOCHOL™ PF, a near-term therapeutic medicine for presbyopia alongside other innovative therapies to treat Cataract and Geographic Atrophy,” said Henric Bjarke, CEO. “With our combined teams, we have the right expertise to develop and successfully launch innovative products with the potential to be first and best in class in ophthalmic medicines.” Mr. Bjarke brings extensive commercial and operational leadership experience in the biopharmaceutical industry, with a focus on ophthalmology, hematology, and orphan diseases. He has held senior roles at several successful companies including, Inozyme Pharma, Ophthotech, Alexion Pharmaceuticals, (OSI) Eyetech, and Pharmacia. “The merger of Tenpoint and Visus is a pivotal moment in the evolution of both companies. As Board Chair, I am excited about the opportunity to collaborate with the new leadership team to commercialize BRIMOCHOL™ PF and advance innovative products into clinical development to meet unmet needs in ocular diseases,” said David Guyer, MD, Chairman of the Board. About Tenpoint Therapeutics Tenpoint Therapeutics Limited is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts and geographic atrophy. Its lead asset, BRIMOCHOL™ PF, is a novel, pupil-modulating therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately 2 billion people globally. BRIMOCHOL™ PF has completed its first Phase 3 pivotal trial (BRIO-I) and will complete the second pivotal study, BRIO-II, in 2025. This topical ophthalmic is poised for launch in 2026. Tenpoint’s leadership team includes ophthalmic industry luminaries with track records of successful approvals and commercialization of blockbuster drugs. A privately held company, Tenpoint Therapeutics is backed by AdBio Partners, British Patient Capital, Eight Roads, EQT Life Sciences, F-Prime Capital, Hillhouse Capital Management, Qiming Venture Partners USA, Sofinnova Partners, and UCL Technology Fund. To learn more visit tenpointtherapeutics.com and connect on LinkedIn .

Phase 3Executive ChangeCell TherapyAcquisition

14 Nov 2024

·www.prnewswire.com

Presbyopia Treatment Market Set to Reach New Heights with New Therapies and Advancements by 2034 | DelveInsight

The launch of emerging therapies, such as LNZ100 by Lenz Therapeutics, Phentolamine Ophthalmic Solution 0.75% by Viatris and Ocuphire Pharma, BRIMOCHOL PF (VT-1011) by Visus Therapeutics, among others will significantly impact the presbyopia market during the forecast period (2024–2034). LAS VEGAS, Nov. 14, 2024 /PRNewswire/ -- Presbyopia is an age-related refractive condition marked by a gradual decline in near vision, typically emerging between ages 40 and 60. It results from the lens losing elasticity and becoming thicker, harder, and less flexible due to structural protein changes. This impairs the lens's ability to adjust for near vision, reducing accommodative amplitude. Presbyopia can be classified into incipient, functional, absolute, premature, and nocturnal types, each representing different stages and manifestations of the condition. As per DelveInsight's assessment, the total prevalent cases of presbyopia in the 7MM were ~325 million in 2023. These cases are expected to increase at a significant CAGR of 1.1% during the forecast period i.e., 2024–2034. Based on severity, presbyopia was bifurcated into mild and moderate to severe presbyopia, in EU4 and the UK, moderate to severe presbyopia accounted for the maximum number of cases, which was approximately 95 million. Treatment options for presbyopia mainly consist of corrective lenses and surgical procedures. Non-invasive methods, such as reading glasses, bifocals, and progressive lenses, enhance vision at different distances. Contact lenses, including multifocal and monovision types, present another option. Surgical treatments like LASIK, conductive keratoplasty, and corneal inlays modify the eye's focusing capabilities. Recently, eye drops like pilocarpine hydrochloride have gained attention as a promising treatment, as they temporarily enhance near vision by constricting the pupil to improve depth of field. For non-drug treatments, reading glasses enable clear vision for tasks up close, while bifocals combine two prescriptions in a single lens to correct both distance and near vision. Progressive lenses provide a smooth transition between different vision zones with no visible lines. Contact lenses designed for presbyopia, like multifocal or accommodating lenses, offer greater convenience and a broader field of vision compared to glasses. For those looking for a more lasting solution, LASIK surgery can correct presbyopia by reshaping the cornea, although it tends to be more effective for younger individuals with stable vision needs. Conductive keratoplasty uses radiofrequency energy to enhance near vision by creating small spots on the cornea, serving as a non-invasive option. Corneal inlays involve inserting a tiny device into the cornea to enhance near vision while maintaining distance vision. Two FDA-approved treatments, VUITY and QLOSI, represent significant advancements in ophthalmology. Learn more about the FDA-approved presbyopia drugs @ Drugs for Presbyopia Treatment VUITY (1.25% pilocarpine HCl ophthalmic solution), developed by Allergan, is a groundbreaking treatment for presbyopia that received FDA approval in October 2021. This prescription eye drop functions by constricting the pupil, which improves near and intermediate vision while minimally impacting distance vision. Utilizing the miotic effects of pilocarpine, VUITY enhances focus for close-range activities, presenting a non-invasive alternative to reading glasses. Its approval represents a significant step forward in managing presbyopia, offering patients a convenient and effective solution to relieve the symptoms associated with the condition. QLOSI (0.4% pilocarpine hydrochloride ophthalmic solution), developed by Orasis Pharmaceuticals, is a new treatment for presbyopia that received approval from the US FDA in October 2023. This formulation utilizes pilocarpine, a cholinergic muscarinic agonist, to enhance the eye's ability to focus on nearby objects. The launch of QLOSI is expected in the latter half of 2024, providing patients with a non-surgical option for addressing age-related vision deterioration. To know more about presbyopia treatment options, visit @ New Treatment for Presbyopia The dynamics of the presbyopia treatment market are anticipated to change during the forecast period as companies across the 7MM are diligently working towards the development of novel treatment options to combat the existing treatment-based unmet needs. Key players, such as Viatris and Ocuphire Pharma (Phentolamine Ophthalmic Solution 0.75%), Visus Therapeutics (BRIMOCHOL PF), Lenz Therapeutics (LNZ100), and others are involved actively in developing potential treatment scopes. Discover which therapies are expected to grab major presbyopia market share @ Presbyopia Market Report LNZ100, developed by Lenz Therapeutics, is an experimental treatment for presbyopia that is currently progressing through Phase III clinical trials. This medication works by targeting and modulating the intraocular muscles to restore the eye's ability to focus on nearby objects, which is a common problem associated with aging. LNZ100 utilizes a unique mechanism of action that selectively modulates specific receptors in the eye to improve accommodation. Administered as eye drops, LNZ100 provides a non-invasive alternative to surgical treatments. The company intends to submit a New Drug Application (NDA) to the FDA in mid-2024, with plans for a market launch in the second half of 2025, establishing it as a significant therapeutic option for presbyopia management. BRIMOCHOL PF (VT-1011) is a drug under development by Visus Therapeutics aimed at treating presbyopia. This combination therapy includes carbachol and brimonidine tartrate and is designed to enhance near vision by utilizing its pharmacodynamic properties. Currently, BRIMOCHOL PF is in Phase III of clinical development. Following promising results from Phase II trials, it has advanced to this crucial stage, where the primary focus is to validate its therapeutic effects and detect any possible side effects before pursuing regulatory approval for market launch. The company plans to submit its New Drug Application (NDA) in the latter half of 2024, intending to provide a new treatment option for presbyopia. Phentolamine Ophthalmic Solution 0.75%, being developed by Viatris and Ocuphire Pharma, aims to treat presbyopia. This solution enhances near vision temporarily while maintaining distance vision, providing a non-surgical option to reading glasses or contact lenses. The development of Phentolamine Ophthalmic Solution 0.75% is in the final phases of clinical trials. It has successfully finished Phase II studies, which showed its efficacy and safety for the intended purpose. The product is currently in Phase III clinical trials to further verify its effectiveness and safety before pursuing regulatory approval. Discover more about drugs for presbyopia in development @ Presbyopia Clinical Trials The anticipated launch of these emerging therapies for presbyopia are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the presbyopia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for presbyopia is expected to grow from USD ~17 billion in 2023 with a CAGR of 3.2% by 2034. The anticipated increase in market size is driven by advancements in treatment options, greater healthcare access, and a rising incidence of the condition, which together foster a higher demand for innovative and effective therapies. DelveInsight's latest published market report titled as Presbyopia Market Insight, Epidemiology, and Market Forecast – 2034 will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the presbyopia country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The presbyopia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalent Cases of Presbyopia Total Diagnosed Prevalent Cases of Presbyopia Gender-specific Diagnosed Prevalent Cases of Presbyopia Age-specific Diagnosed Prevalent Cases of Presbyopia Severity-specific Diagnosed Prevalent Cases of Presbyopia The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM presbyopia market. Highlights include: 11-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this presbyopia market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the presbyopia market. Also, stay abreast of the mitigating factors to improve your market position in the presbyopia therapeutic space. Related Reports Presbyopia Pipeline Presbyopia Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key presbyopia companies, including Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, among others. Myopia Market Myopia Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key myopia companies such as Vyluma, Inc., Sydnexis, Inc., Ocumension limited, Santen Pharmaceutical, Cloudbreak therapeutics, Nevakar, Inc., Eyenovia, Stuart Therapeutics, Cellix Bio, JeniVision, Zhaoke Ophthalmology, among others. Myopia Pipeline Myopia Pipeline Insight – 2024 report provides comprehensive insights into pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myopia companies involved, such as Vyluma, Inc., Sydnexis, Inc., Ocumension limited, Santen Pharmaceutical, Cloudbreak therapeutics, Nevakar, Inc., Eyenovia, Stuart Therapeutics, Cellix Bio, JeniVision, Zhaoke Ophthalmology, among others. Myopia Progression Market Myopia Progression Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key myopia progression companies such as Johnson & Johnson Vision Care Inc, Beijing Airdoc Technology Co., Ltd, Essilor International, Menicon Co., Ltd., SightGlass Vision Inc, Indizen Optical Technologies, S.L.U., Bausch & Lomb Incorporated, Coopervision Inc, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Drug ApprovalPhase 2

18 Aug 2024

·www.ophthalmologytimes.com

Visiox Pharmaceuticals announces merger with Ocuvex Therpeutics

Going forward, the company will operate under the Ocuvex name, building on Visiox's commitment to disrupting the ophthalmic market through high-level collaboration with eye care professionals. Visiox Pharmaceuticals Inc announced it has entered into a definitive merger agreement with Ocuvex Therapeutics Inc. According to a news release, Ocuvex, a privately held ophthalmic pharmaceutical company focused on developing and commercializing novel therapies for glaucoma and other disorders, has a pipeline of near-term ophthalmic medicines. The companies noted the strategic combination will position the newly combined entity as a potential leader in the eye care sector with a portfolio of ophthalmic medicines. Visiox's products include omidenepag isopropyl ophthalmic solution (Omlonti), licensed by Visiox from Santen Pharmaceuticals a year ago. Another, PDP-716 (brimonidine) 0.35%, is the next closest to the market. It is a once-daily solution that the company has been hoping to launch in early 2025. It also has SDN-037 (difluprednate) 0.04%, which will grow Ocuvex's market presence and accelerate the commercialization of these therapeutics. Going forward, the company will operate under the Ocuvex name, building on Visiox's commitment to disrupting the ophthalmic market through high-level collaboration with eye care professionals. "The combination of Visiox and Ocuvex makes for a perfect match," Ryan S. Bleeks, CEO of Visiox, said in the news release. "We have reached significant milestones with our products and Ocuvex is in a great position to take these advancements forward and bring them to market faster and emerge as a future leader in eye care."

AcquisitionDrug Approval

100 Deals associated with Brimonidine Tartrate

External Link

KEGG	Wiki	ATC	Drug Bank
D02076	Brimonidine Tartrate	S01EA05 D11AX21	DB00484

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Eye Redness	US	Bausch & Lomb, Inc.	22 Dec 2017
Rosacea	US	Galderma Laboratories LP	23 Aug 2013
Glaucoma	JP	Senju Pharmaceutical Co., Ltd.	18 Jan 2012
Ocular Hypotension	US	AbbVie, Inc.	19 Aug 2005
Glaucoma, Open-Angle	US	Allergan, Inc.	06 Sep 1996
Ocular Hypertension	US	Allergan, Inc.	06 Sep 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Conjunctivitis, Allergic	Phase 3	US	Bausch & Lomb, Inc.	18 Nov 2022
Seasonal allergic conjunctivitis	Phase 3	US	Bausch & Lomb, Inc.	18 Nov 2022
Erythema	Phase 3	US	Bausch & Lomb, Inc.	07 Nov 2013
Hyperemia	Phase 3	US	Bausch & Lomb, Inc.	07 Nov 2013
Retinal Detachment	Phase 2	US	Allergan Ltd. (Ireland)	01 Nov 2009
Retinal Detachment	Phase 2	IN	Allergan Ltd. (Ireland)	01 Nov 2009
Retinal Detachment	Phase 2	IL	Allergan Ltd. (Ireland)	01 Nov 2009
Retinal Detachment	Phase 2	PH	Allergan Ltd. (Ireland)	01 Nov 2009
Retinal Detachment	Phase 2	KR	Allergan Ltd. (Ireland)	01 Nov 2009
Retinal Detachment	Phase 2	GB	Allergan Ltd. (Ireland)	01 Nov 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05360784 (CTgov)	Phase 3	Eye Redness	380	Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation (Brimonidine Tartrate Preservation-free)	adnljcqkqb(nouamwyfsh) = hnjjvetjmo jshzcbcsat (quspdtvuil, rhcabbmxuf - fopdkedgdy) View more	-	26 Aug 2024
				Lumify® (brimonidine tartrate ophthalmic solution 0.025%) (Lumify®)	adnljcqkqb(nouamwyfsh) = jiyackbkau jshzcbcsat (quspdtvuil, oqpkrwgpnt - sxemesgbxt) View more
ARVO2023	Not Applicable	Glaucoma	-	Liposomal formulation with brimonidine, ribitol, and taurine	kezzitrqmo(yhhhhyekck) = calvifammv aftgqjdswy (ndpgyeiwtm ) View more	-	23 Apr 2023
				Liposomal formulation with brimonidine, ribitol, taurine, and HPMC	kezzitrqmo(yhhhhyekck) = jsxkjtsjqa aftgqjdswy (ndpgyeiwtm ) View more
NCT03418727 (CTgov)	Phase 2	Dry Eye Syndromes	84	Corticosteroid+Brimonidine (Brimonidine and Corticosteroid Combination Therapy)	dojrkpburz(tkvvhodoxc) = xokndfmspp tnxwrjbuyb (iqtbcumzca, kojtkaxilt - ikhdghaixf) View more	-	06 Jul 2022
				Brimonidine (Brimonidine Monotherapy)	dojrkpburz(tkvvhodoxc) = ipggrveqcg tnxwrjbuyb (iqtbcumzca, inunpewwur - fthneyfwrc) View more
NCT03785340 (CTgov)	Phase 3	Xerophthalmia	252	Brimonidine Tartrate	wjahqcmyxl(uizgenpyla) = doepziypdi hrwyywpmqj (lcljzkoqms, eytiyjdygp - tyzjjlnxkj) View more	-	06 Jun 2022
NCT03760185 (CTgov)	Phase 2	Intraoperative floppy iris syndrome (IFIS)	13	Brimonidine Tartrate (Brimonidine Tartrate 0.2%)	rvnavmsdvi(dnoioxgvuj) = ojcbhhhqve vzenzojyun (lpzihqbusb, uczfiyofiz - dlpdwcmdqb) View more	-	20 Apr 2022
				Brimonidine Tartrate (Control - Untreated)	rvnavmsdvi(dnoioxgvuj) = hprtlmurak vzenzojyun (lpzihqbusb, sditwskmcs - xqqgpdztsw) View more
NCT03450629 (CTgov)	Phase 3	Glaucoma, Open-Angle	682	Brimonidine Tartrate Ophthalmic Suspension (PDP-716)	rrzdtipnhh(yvlfkmgtzc) = ptldftexut lzrxmwxztp (tswdwsaxlz, leismdubqp - qwwlnqlhoh) View more	-	15 Feb 2022
				Brimonidine Tartrate Ophthalmic Solution (Brimonidine Tartrate Ophthalmic Solution)	rrzdtipnhh(yvlfkmgtzc) = zltemdlnio lzrxmwxztp (tswdwsaxlz, rlschbwdkn - zevzehubao) View more
AAI2021	Not Applicable	Mastocytosis	-	Vancomycin	pjmdmmxlox(byqalguhui) = The use of VCM is associated with several potential adverse reactions czyruholub (vdkrdszfrx ) View more	-	01 May 2021
NCT03323164 (CTgov)	Phase 4	Glaucoma, Open-Angle \| Low Tension Glaucoma	35	Brimonidine Tartrate (Brimonidine)	pwsabegekb(fhpvdcfdbx) = dhmjcaakxp qesywzkiyt (zswiqhyrzm, urdiqykvop - zmthkplvqj) View more	-	31 Dec 2020
				Timolol Maleate (Timolol)	pwsabegekb(fhpvdcfdbx) = wtjxrqgjmr qesywzkiyt (zswiqhyrzm, kfyermukpz - xkgvziqcrc) View more
NCT02385240 (CTgov)	Phase 3	Rosacea	552	Brimonidine Topical Gel, 0.33 percent (Perrigo) (Test Product)	dljmbxtulw(sbwhvjcgpt) = vwrxmvrgyz ettciprwiv (typujbsduz, sjacfyikno - quinppeiyh) View more	-	14 Dec 2020
				Brimonidine Topical Gel, 0.33 percent (Reference) (Reference Product)	dljmbxtulw(sbwhvjcgpt) = rcmldbwchy ettciprwiv (typujbsduz, ecbwjnpvgc - mqqzennebx) View more
NCT02289352 (CTgov)	Phase 3	Rosacea \| Erythema	462	placebo	gtnxklsvik(gshccordcs) = aaetqzugjh cwpumypnpy (smwxcolgha, dcuaxgiipi - zfxpbwsmql) View more	-	14 Jan 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis